Andrei Iagaru
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Andrei Iagaru sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).
Andrei Iagaru: 13 sponsored US clinical trials, 1 recruiting.
Andrei Iagaru sponsors 13 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 11 completed. 0 of these trials are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Former Smoker, with 1 trials.
Top-decile sponsor footprint
Andrei Iagaru ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
13 total, page 1 of 1
99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT
NCT05891769
Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer
NCT03698370
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
NCT04264208
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
NCT03949517
68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer
NCT03831711
18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules
NCT03824535
68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
NCT03809078
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
NCT03733210
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
NCT02673151
68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer
NCT03113617
68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery
NCT02678351
68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
NCT02624518
18F-FSPG PET/CT for Cancer Patients on Therapy
NCT02599194
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 10 |
What is open in the Andrei Iagaru pipeline
1 recruiting of 13 indexed (8% open); 11 completed (85%).
Phase mix: 0 late (III/IV) vs 13 early (I/II) (early-phase heavy).
Top condition: Former Smoker (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Andrei Iagaru: open-pipeline peers nationwide
Peers matched on 13 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Andrei Iagaru sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 13 trials (± recruiting share)
- Adaptimmune · 13 trials · 0% recruiting
- Agennix · 13 trials · 0% recruiting
- Akili Interactive Labs · 13 trials · 0% recruiting
- Alumis · 13 trials · 8% recruiting
Sponsors near 8% open enrollment (± trial volume)
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
- Fresenius Medical Care North America · 8% recruiting · 13 trials
- LG Chem · 8% recruiting · 13 trials
Related
What to do with this Andrei Iagaru page
13 registered trials is a research-attention snapshot, not an endorsement of Andrei Iagaru or any single study.
- 1 of Andrei Iagaru's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Former Smoker is the condition Andrei Iagaru studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Former Smoker trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Andrei Iagaru pipeline card: 13 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.